JP2016113410A - Dizziness improver - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a novel use of royal jelly.SOLUTION: A dizziness improver comprises royal jelly or a processed product thereof as an active ingredient.SELECTED DRAWING: None

Description

  The present invention relates to a dizziness improving agent.

  Royal jelly is known to have many physiological activities such as growth promoting action, life-prolonging effect, and antitumor action. For example, Patent Document 1 discloses an antidepressant composition containing royal jelly or a water-soluble fraction thereof as an active ingredient.

JP 2004-131407 A

  An object of this invention is to provide the novel use of a royal jelly.

  The present inventors have found that royal jelly has an effect of improving the symptom of “being aware of yourself and its surroundings” and the symptom of “blackout of vision”. The present invention is based on this novel finding.

  That is, this invention provides the dizziness improving agent which contains royal jelly or its processed material as an active ingredient.

  Since the above dizziness improving agent can significantly improve the symptoms of rotational dizziness and standing dizziness, it may be used for improving rotational dizziness or for dizziness.

  The dizziness-improving agent of the present invention can also be used as a dizziness-improving food, health food, functional food, dietary supplement, supplement, food for specified health use, or pharmaceutical product. Royal jelly has been conventionally used as food and the like, and safety to living bodies has been established. Therefore, the dizziness-improving food, health food, functional food, nutritional supplement, supplement, food for specified health use, or medicine can be continuously taken for a long period of time.

  According to this invention, the dizziness improving agent which contains a royal jelly or its processed material as an active ingredient is provided.

  Hereinafter, embodiments for carrying out the present invention will be described in detail. However, the present invention is not limited to the following embodiments.

  The dizziness improving agent of the present invention contains royal jelly or a processed product thereof as an active ingredient.

  Royal jelly is well known as a bee product. Royal jelly is a milky product made by adding fatty acids secreted from the maxillary gland to a transparent liquid rich in protein secreted by the worker bees from the hypopharyngeal gland. Royal jelly is known to contain water, protein, carbohydrates, lipids, ash, free amino acids, vitamins, minerals and the like.

  The processed product of royal jelly is not particularly limited as long as it has a physiological action (for example, dizziness improving action) of royal jelly. Specific examples of processed products of royal jelly include a royal jelly concentrate or dilution obtained by concentrating or diluting royal jelly, royal jelly powder obtained by drying royal jelly and powdered, royal jelly ethanol extract obtained by extracting royal jelly with an organic solvent such as ethanol, etc. Examples include royal jelly organic solvent extract and enzymatically degraded royal jelly obtained by treating royal jelly with a proteolytic enzyme. Among these, an enzymatically decomposed royal jelly is preferable because the effect of improving dizziness is more remarkably exhibited.

  In the dizziness-improving agent of the present invention, the above-mentioned royal jelly and the processed product of royal jelly may be used alone or in combination of two or more.

  Royal jelly can be obtained, for example, as a beekeeping product according to a conventional method.

  The royal jelly concentrate can be obtained, for example, by removing water from the royal jelly. The royal jelly dilution can be obtained, for example, by adding water to the royal jelly.

  The royal jelly powder can be obtained by pulverizing the royal jelly by a known method in this technical field such as freeze drying and spray drying. Alternatively, royal jelly powder may be obtained by freeze-drying or spray-drying and then pulverizing with a pulverizer (eg, pin mill, hammer mill, ball mill, jet mill).

  The enzymatically degraded royal jelly can be obtained, for example, by treating the royal jelly with a proteolytic enzyme. Examples of the proteolytic enzyme include an enzyme having an endopeptidase action, an enzyme having an exopeptidase action, and an enzyme having both an endopeptidase action and an exopeptidase action. As the proteolytic enzyme, an enzyme having at least one of an endopeptidase action and an exopeptidase action may be used. An enzyme having at least an endopeptidase action is preferable, and has both an endopeptidase action and an exopeptidase action. Enzymes are more preferred. Here, the endopeptidase action is an action that breaks the peptide bond of the non-terminal amino acid, and the exopeptidase action is an action that breaks the peptide bond of the terminal amino acid.

  Proteolytic enzymes include an enzyme having only an exopeptidase action, an enzyme having only an endopeptidase action, and an enzyme having both an endopeptidase action and an exopeptidase action. An enzyme having both an endopeptidase action and an exopeptidase action is referred to as an "enzyme having an endopeptidase action" when the endopeptidase action is stronger, and an exopeptidase action when the exopeptidase activity is stronger. In the case where the exopeptidase action and the endopeptidase action are equivalent or almost equivalent, it is designated as “an enzyme having both an endopeptidase action and an exopeptidase action”. In addition, equivalent or substantially equivalent means that the ratio (activity ratio) of the endopeptidase action to the exopeptidase action is 0.8 to 1.2 times.

  Examples of the enzyme having an endopeptidase action include animal-derived endopeptidases (eg, trypsin, chymotrypsin, etc.), plant-derived endopeptidases (eg, papain, etc.), lactic acid bacteria, yeasts, molds, Bacillus subtilis, actinomycetes, etc. Endopeptidases derived from these microorganisms. More specific examples of an enzyme having an endopeptidase action include a Bacillus subtilis-producing peptidase (trade name: orientase 22BF, nucleicin), a Bacillus licheniformis-producing peptidase (trade name). : Alcalase), Bacillus stearothermophilus production peptidase (trade name: Protease S), Bacillus amyloliquefaciens production peptidase (trade name: Neutase), Bacillus product peptidase production Name: Protamex).

  Examples of the enzyme having an exopeptidase action include carboxypeptidase, aminopeptidase, or exopeptidase derived from microorganisms such as lactic acid bacteria, Aspergillus or Rhizopus. More specific examples of an enzyme having an exopeptidase action include Aspergillus oryzae-producing peptidase (trade names: Umamizyme G, Promod 192P, Promod 194P, Sumiteam FLAP), Aspergillus soe (Aspergillus production) (Brand name: Sternzyme B15024), Aspergillus genus peptidase (Brand name: Cochlase P), Rhizopus oryzae production peptidase (Brand name: Peptidase R).

  Examples of the enzyme having both an endopeptidase action and an exopeptidase action include pancreatin, pepsin and the like. More specific examples of an enzyme having both an endopeptidase action and an exopeptidase action include Streptomyces griseus-producing peptidase (trade name: actinase AS), Aspergillus oryzae production Peptidase (trade name: Protease A, flavorzyme), Aspergillus meleus-produced peptidase (trade name: Protease P) can be mentioned.

  The reaction conditions for treating royal jelly with proteolytic enzymes (amount of proteolytic enzyme used, temperature during reaction, pH, reaction time, etc.) may be appropriately set according to the type of proteolytic enzyme used. . As specific reaction conditions, for example, when using actinase AS (Kaken Pharmaceutical Co., Ltd.) having both endopeptidase action and exopeptidase action as a proteolytic enzyme, the amount of proteolytic enzyme used is 1 g per 100 g of royal jelly, and the temperature during the reaction. Examples are 45 to 55 ° C., pH 8.5 to 9.5, and reaction time 2 to 4 hours.

  The royal jelly organic solvent extract can be obtained, for example, by extracting royal jelly using an organic solvent such as ethanol, methanol, propanol, and acetone as a solvent. The extraction time can be appropriately set according to the form of the royal jelly used as the raw material, the type and amount of the solvent, the temperature during the extraction, the stirring conditions, and the like. After extraction, solid content may be removed by filtration, centrifugation, or the like. The extracted solution may be used as it is, or the solvent may be removed from the solution and used as a concentrated solution or powder. The royal jelly organic solvent extract is preferably a royal jelly ethanol extract.

  Commercially available products may be used as the royal jelly and the processed product of the royal jelly. Specific examples of royal jelly and processed products of royal jelly include, for example, royal jelly FD powder (manufactured by Nakahara Co., Ltd.), royal jelly extract SF (manufactured by Matsuura Pharmaceutical Co., Ltd.), deproteinized royal jelly powder F (manufactured by Maruzen Pharmaceutical Co., Ltd.), Deproteinized royal jelly extract (manufactured by API Corporation) and the like can be mentioned.

  The dizziness improving agent of the present invention contains royal jelly or a processed product of royal jelly as an active ingredient. Can alleviate the symptoms.

  Vertigo can be classified into rotational dizziness, floating dizziness, standing dizziness, etc. according to the symptom. A typical symptom of rotational dizziness is being aware that you or your surroundings are turning. A typical symptom of floating dizziness is a feeling of non-rotational wandering that makes the body flutter or stagger. Typical symptoms of dizziness are blood draw, dark vision (blackout), fainting, etc.

  The dizziness-improving agent of the present invention can significantly improve the symptom of being aware of itself or surroundings and the symptom of visual blackout. It can be suitably used as a standing glare improving agent (that is, a standing glare improving agent).

  The dizziness-improving agent of the present invention may contain only an active ingredient, royal jelly or a processed product of royal jelly, and may further contain other components as long as the effects of the present invention are not hindered. Examples of other components include pharmaceutically acceptable components (for example, excipients, binders, lubricants, disintegrants, emulsifiers, surfactants, bases, solubilizers, suspending agents). , Food-acceptable ingredients (eg minerals, vitamins, flavonoids, quinones, polyphenols, amino acids, nucleic acids, essential fatty acids, cooling agents, binders, sweeteners, disintegrants, lubricants, colorants Fragrances, stabilizers, preservatives, sustained release regulators, surfactants, solubilizers, wetting agents).

  The dizziness-improving agent of the present invention can be used at a dose of 1 mg or more and 10 g or less per day for an adult having a body weight of 60 kg, preferably in a dose of 50 mg or more and 8 g or less, preferably 300 mg or more and 3 g or less. More preferably, it is used at a dose of 300 mg to 1.5 g. The dose can be appropriately set within the above-mentioned range depending on factors such as the health condition of the person who ingests, the administration method, and combinations with other agents.

  The vertigo improving agent of the present invention may be administered orally (ingested) or parenterally. The dizziness-improving agent of the present invention may be administered once a day as long as the amount of active ingredient per day is within the above-mentioned range, or divided into a plurality of times such as twice a day or three times a day. It may be administered.

  Since the vertigo improving effect is more prominent, the vertigo improving agent of the present invention is orally administered once a day in an amount of 300 mg to 1.5 g, in terms of the amount of active ingredient, to an adult with a body weight of 60 kg. It is preferable to be used.

  The dizziness improving agent of the present invention may be in any shape such as solid, liquid, paste and the like. The form of the dizziness improving agent of the present invention may be, for example, an uncoated tablet, sugar-coated tablet, granule, powder, tablet, or capsule (hard capsule, soft capsule, seamless capsule). The dizziness-improving agent of the present invention can be prepared, for example, by mixing the royal jelly or the processed product of the royal jelly, which is an active ingredient, with other components as necessary, and molding the mixture into the above dosage form.

  The dizziness-improving agent of the present invention can be used as a pharmaceutical, a quasi-drug, and a food as well as added to a pharmaceutical, a quasi-drug, and a food. The food is preferably a food that emphasizes the tertiary function of the food (physical condition control function, that is, dizziness improving function, etc.). Examples of foods in which the tertiary function of food is emphasized include health foods, functional foods, nutritional supplements, supplements, and foods for specified health use.

  The pharmaceutical, quasi-drug or food comprising the dizziness improving agent of the present invention, or the pharmaceutical, quasi-drug or food containing the dizziness improving agent of the present invention is for dizziness improvement, rotational dizziness improvement, or standing dizziness improvement It may be used, and an indication such as “improving dizziness” or “improving standing dizziness” may be attached.

  The content of the dizziness-improving agent of the present invention in pharmaceuticals, quasi-drugs and foods depends on the types of pharmaceuticals, quasi-drugs and foods, etc., so that the amount of active ingredient taken per day is within the above-mentioned range. May be set as appropriate.

  When the dizziness-improving agent of the present invention is used as food itself or added to food, the form of the food is not particularly limited. For example, beverages (soft drinks such as coffee, juice, tea drinks, milk drinks, lactic acid bacteria Beverages, yogurt drinks, carbonated drinks, etc.), spreads (such as custard cream), pastes (fruit paste, etc.), pastries (chocolate, donuts, pies, cream puffs, gums, jelly, candy, cookies, cakes, puddings, etc.) , Japanese confectionery (Daifuku, rice cake, bun, castella, anmitsu, mutton, etc.), ice confectionery (ice cream, popsicle, sherbet, etc.), foods (curry, beef bowl, miso soup, miso soup, soup, meat sauce, pasta, pickles , Jam, etc.), seasonings (dressing, sprinkles, umami seasonings, soup ingredients, etc.)

  The dizziness-improving agent of the present invention is used as a food in which the tertiary function of the food is emphasized (for example, health food, functional food, dietary supplement, supplement or food for specified health use), or the tertiary function of the food is emphasized. In addition to the food form described above, the form of the food in which the tertiary function of the food is emphasized is, for example, uncoated tablets, dragees, granules, powders, tablets, capsules (hard capsules, Soft capsules and seamless capsules).

  When the vertigo improving agent of the present invention is used as a pharmaceutical product or quasi-drug itself or added to a pharmaceutical product or quasi-drug, the form of the pharmaceutical product or quasi-drug is not particularly limited. Dragees, granules, powders, tablets, and capsules (hard capsules, soft capsules, seamless capsules) may be used.

  The manufacturing method of the pharmaceutical, quasi-drug, or food to which the vertigo improving agent of the present invention is added is not particularly limited, and can be appropriately followed by a known method. For example, the vertigo-improving agent of the present invention is mixed with an intermediate product or final product in the manufacturing process of a pharmaceutical product, quasi-drug or food to obtain a pharmaceutical product, quasi-drug or food used for the above-mentioned use. Can do.

  Hereinafter, the present invention will be described more specifically based on examples. However, the present invention is not limited to the following examples.

〔Test method〕
The subjects were 250 healthy volunteers who were allowed to drink enzyme-degraded royal jelly (trade name: Apitherapy-prepared royal jelly powder, manufactured by Yamada Bee Farm Head Office, 1,333 mg / day) every day for 8 weeks. Conducted a questionnaire to evaluate each symptom at the time of entry (before the start of drinking) and after drinking for 8 weeks, with a four-point score (1: rare, 2: rare, 3: occasionally, 4: frequent) did.

  A cross tabulation table was created from the questionnaire results, and the scores before and after drinking were analyzed by Wilcoxon signed rank sum test.

Table 1 shows an analysis result of a symptom, “Do you recognize yourself and your surroundings?” Table 2 shows the analysis result of the symptom “blackout of view”.

  The use of royal jelly has been observed to reduce the frequency of occurrence of symptoms such as “Do you recognize yourself or your surroundings?” Or to suppress the occurrence of symptoms, and the symptoms are significantly improved at p = 0.0369. (Table 1). Similarly, a decrease in the frequency of occurrence of the symptom “blackout of sight” or suppression of the occurrence of the symptom was observed, and the symptom was significantly improved at p = 0.156 (Table 2).

Claims (5)

  A dizziness improving agent containing royal jelly or a processed product thereof as an active ingredient.   The vertigo improving agent according to claim 1, which is used for improving rotational vertigo.   The dizziness-improving agent according to claim 1, which is used for improving standing dizziness.   A food for vertigo improvement, a health food, a functional food, a dietary supplement, a supplement, or a food for specified health use, comprising the vertigo improving agent according to any one of claims 1 to 3.   The pharmaceutical for vertigo improvement containing the vertigo improving agent as described in any one of Claims 1-3.